Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature

Authors

  • Kashif Aziz Department of Medicine, Icahn School of Medicine Mount Sinai, Queens Hospital Center, Jamaica, New York
  • Amir Shahbaz Department of Medicine, Icahn School of Medicine Mount Sinai, Queens Hospital Center, Jamaica, New York
  • Muhammad Umair Department of Medicine, Icahn School of Medicine Mount Sinai, Queens Hospital Center, Jamaica, New York
  • Isaac Sachmechi Department of Medicine, Icahn School of Medicine Mount Sinai, Queens Hospital Center, Jamaica, New York

DOI:

https://doi.org/10.17179/excli2018-1357

Keywords:

avelumab, hypothyroidism, hypoadrenalism, endocrinopathies, Immune Check Point Inhibitors, Pd-L1

Abstract

Avelumab is an anti-PD-L1 (programmed death-ligand 1) immune checkpoint inhibitor (ICIs) and the monoclonal antibody that constitutes a major development in the immunotherapy of cancer. In 2017, The European Medicine Agency (EMA) approved it as an orphan drug for treatment of gastric cancer. Avelumab has recently been approved in the United States, Europe and Japan for treatment of metastatic Merkel cell carcinoma (MCC). Avelumab inhibits the interaction of Programmed cell death protein 1 (PD-1) on immune cells with PD-L1 on tumor cells, thus banishing immunosuppressive signals and leading to enhanced immune cell activation. Here we are revealing a case of the patient with metastatic gastric cancer receiving avelumab with the development of undesirable endocrinopathies during the course of treatment. We suggested that patients receiving avelumab immunotherapy should be monitored for signs and symptoms of thyroiditis, hypothyroidism and adrenal insufficiency, which may require immediate attention and supportive treatment by immunosuppression and respective hormone replacement.

Downloads

Published

2018-06-06

How to Cite

Aziz, K., Shahbaz, A., Umair, M., & Sachmechi, I. (2018). Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature. EXCLI Journal, 17, 526–530. https://doi.org/10.17179/excli2018-1357

Issue

Vol. 17 (2018)

Section

Case reports

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).